Decentralized Clinical Trials in a Covid-19 Landscape


YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.

• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.

Related Videos
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2024 MJH Life Sciences

All rights reserved.